ICMR transfers three indigenous biomedical technologies to advance cancer and infectious disease solutions

📌 Summary:

• ICMR, under its Medical Innovations Patent Mitra initiative, licensed three indigenous biomedical technologies to Indian manufacturers for development and commercialisation
• SHetA2, a first-in-class anti-HPV therapeutic candidate for Cervical Intraepithelial Neoplasia (CIN), licensed to Emcure Pharmaceuticals; selectively kills HPV-induced pre-cancerous/cervical cancer cells while sparing healthy cells
• Two next-generation enteric vaccine technologies (developed at ICMR-NIRBI, Kolkata) licensed to Biological E Ltd: a fusion-construct typhoid vaccine candidate and a recombinant vaccine against Salmonella typhi/paratyphi and Shigella
• Goal: translate publicly funded research into affordable healthcare and strengthen India's biomedical innovation ecosystem and self-reliance
• SHetA2 developed via ICMR-NICPR collaboration with Stephenson Cancer Center, University of Oklahoma (USA)

🎯 UPSC Relevance: GS3 S&T — indigenous biotech, technology transfer, IPR, self-reliance in healthcare; public-funded research to commercialisation

📝 Prelims Facts:

• SHetA2 = anti-HPV therapeutic candidate for cervical cancer; licensed to Emcure Pharmaceuticals
• ICMR-NIRBI = ICMR National Institute of Research in Bacterial Infections, Kolkata
• Enteric vaccine technologies licensed to Biological E Ltd; initiative = Medical Innovations Patent Mitra

🔑 Key Term: Technology transfer — licensing of research/IP from a public institution to industry for manufacturing and commercialisation